The Scripps Research Institute - Lead Identification Lead ID Home Work With Us

Work With Us


Working With Us

For academic collaborators, a popular way to access our expertise and facilities is through NIH-sponsored mechanisms. Industrial and academic collaborators can also directly sponsor specific screening activities. Please contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call us at either (561) 228-2150 or (561) 228-2101 if you have any questions or need assistance with any of the opportunities listed below.

 

NIH-Funded Opportunities

The NIH has announced grant opportunities that fund the screening of Scripps’ Drug Discovery Library. This 640,000 compound library is unique to Scripps. Please click on the links below to be directed to information related to each grant:

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
arrow PA-19-056

Posted Date: November 5, 2019
Expiration Date: January 8, 2022
Participating Organizations: All NIH institutes
Funding Opportunity Purpose: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Drug discovery research can be included: 1) assay development; 2) HTS/HCS primary screen implementation to identify initial screening hits (target-focused or phenotypic screens); 3) hit validation; 4.) medicinal chemistry SARs; and 5.) lead-optimization. Five years of support is adequate to support assay transfer, high throughput drug discovery, medicinal chemistry, DMPK pharmacology, target validation and MOA studies as well as preliminary in-vivo experimentation. SRMSC can coordinate all services (1-5) as needed. Entry requires identification of a target and/or phenotypic response, preliminary assay data and a source of biologics (i.e. cell line, proteins, peptides) Projects are reviewed and transferred to SRMSC to provided preliminary screening data for grant application.

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
arrow PA-19-053

Posted Date: November 5, 2018
Expiration Date: January 8, 2022
Participating Organizations: All NIH institutes
Funding Opportunity Purpose:The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Drug discovery research can be included: 1) assay development; 2.) Pilot or small library HTS screening; 3) larger HTS/HCS primary screen implementation to identify initial hits (target-focused or phenotypic screens). limited to a budget of no more than $275,000 over a maximum 2 year span.

Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01)
arrow PAR-18-511

Posted Date: December 19, 2017
Expiration Date: January 8, 2021
Participating Organizations: NICHD
Funding Opportunity Purpose: The purpose of this funding opportunity announcement (FOA) is to encourage grant applications that will identify molecular targets for pregnancy associated/induced disorders and will lead to the development of new safer and more effective medications for use in pregnancy. Research areas appropriate for this announcement include: Identification of new targets from already identified critical molecular pathways using high throughput screening; Development of novel therapeutics based on newly identified targets; and Safety and pharmacokinetic studies of the above medications.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19)
arrow PAR-18-231

Posted Date: November 21, 2017
Expiration Date: February 25, 2020
Participating Organizations: NIMH, NIDA, NIAAA
Funding Opportunity Purpose: The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies. For NIMH, an application to this FOA can include the following projects or components ranging from ligand discovery (or early stage device development) and testing in preclinical assays through human Phase IIa studies of novel agents/devices. Examples include, but are not limited to: Ligand discovery for therapeutics development or as clinical research tools (e.g., imaging probes) for novel molecular targets implicated in mental illnesses. Partnerships between academia and industry are strongly encouraged.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U01)
arrow PAR-18-230

Posted Date: November 21, 2017
Expiration Date: February 25, 2020
Participating Organizations: NIMH, NIDA, NIAAA
Funding Opportunity Purpose: The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies. For NIMH, an application to this FOA can include the following projects or components ranging from ligand discovery (or early stage device development) and testing in preclinical assays through human Phase IIa studies of novel agents/devices. Examples include, but are not limited to: Ligand discovery for therapeutics development or as clinical research tools (e.g., imaging probes) for novel molecular targets implicated in mental illnesses. Partnerships between academia and industry are strongly encouraged.

Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21)
arrow PAR-18-721

Posted Date: March 28, 2018
Expiration Date: May 27, 2020
Participating Organizations: NINDS, NIAMS, NEI, NIDA, NIEHS
Funding Opportunity Purpose: This FOA encourages applications for exploratory and developmental translational research projects to identify and develop novel medical countermeasures (drug or biologic) to reduce mortality and morbidity resulting from acute exposures to chemical agents identified by the U.S. Government (USG) as threats to the population. Chemical threat agents are toxic compounds that could be released by a deliberate terrorist attack against civilians, or by accidental or natural disaster causing mass casualties. CounterACT Exploratory/ Developmental Projects in Translational Research (R21) will be utilized to support 1-2 year pilot studies to generate preliminary efficacy data for therapeutics to treat injuries resulting from exposure to these chemicals. Pilot studies may include the creation and validation of screening assays for therapy development, identification of candidate therapeutic targets, and development of proof-of-principle efficacy data for the candidate therapy compounds. It is expected that the preliminary data from these R21 projects will be used in support of research applications for transition to related chemical medical countermeasures research and development programs, to include NIH CounterACT supported milestone-driven Cooperative Agreement programs.

Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54)
arrow PAR-18-657

Posted Date: February 13, 2018
Expiration Date: September 10, 2020
Participating Organizations: NINDS, NIAMS, NEI, NIDA, NIEHS
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.

Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R43/R44)
arrow PA-18-566

Posted Date: January 12, 2018
Expiration Date: January 6, 2021
Participating Organizations: NIMH
Funding Opportunity Purpose: This FOA encourages SBIR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard SBIR guidelines. Drug Discovery/Drug Development in Mental Illness: NIMH is specifically interested in supporting the development of pharmacologic agents, based on novel molecular CNS targets that improve function and minimize the side effects seen with current medications. In addition, compounds targeted for the treatment of pediatric or geriatric psychiatric disorders would also be of interest. Funding could support a range of activities including: development of novel ligand screening assays ( including high throughput) novel chemistry approaches and lead compound identification/optimization.

Alzheimer Centers for Discovery of New Medicines (U54)
arrow RFA-AG-19-010

Posted Date: August 2, 2018
Expiration Date: February 2, 2019
Participating Organizations: NIA
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) invites U54 Cooperative Agreement applications aiming to establish multi-component Alzheimer Centers for the Discovery of New Medicines. The overarching purpose of this Centers program is to improve, diversify and reinvigorate the Alzheimer's disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will 1) design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as AMP-AD, and 2) initiate early stage drug discovery campaigns against the enabled targets. The Center should have the following structure: Administrative and Data Management Core, Bioinformatics and Computational Biology Core, Structural Biology Core, Assay Development and High Throughput Screening Core, Medicinal Chemistry and Chemical Biology Core, Steering Committee, and External Advisory Board.

Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R41/R42)
arrow PA-18-579

Posted Date: January 12, 2018
Expiration Date: January 6, 2021
Participating Organizations: NIMH
Funding Opportunity Purpose: This FOA encourages SBIR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard SBIR guidelines. Drug Discovery/Drug Development in Mental Illness: NIMH is specifically interested in supporting the development of pharmacologic agents, based on novel molecular CNS targets that improve function and minimize the side effects seen with current medications. In addition, compounds targeted for the treatment of pediatric or geriatric psychiatric disorders would also be of interest. Funding could support a range of activities including: development of novel ligand screening assays ( including high throughput) novel chemistry approaches and lead compound identification/optimization.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
arrow PAR-18-762

Posted Date: April 19, 2018
Expiration Date: May 8, 2021
Participating Organizations: NINDS
R01 Research Project: This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. Activities for R61 phase include Assay development, validation and optimization for High-Throughput Screening (HTS). Activities for the R33 phase includes HTS, medicinal chemistry, assessment of initial pharmacokinetic and optimization of therapeutic agent(s) for in vivo testing.

Assay development and screening for discovery of chemical probes or therapeutic agents (R01)
arrow PAR-17-438

Posted Date: July 27, 2017
Expiration Date: Sep 8, 2020
Participating Organizations: NIMH, NIAID, NCI, NIDA, NIDCD
R01 Research Project: Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize hit set.

Drug Discovery for Nervous System Disorders (R21)
arrow PAR-19-146

Posted Date: Jan 8, 2019
Expiration Date: Jan 8, 2022
Participating Organizations: NIMH, NIA, NIDA
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders.
This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents.
The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA.

Drug Discovery for Nervous System Disorders (R01)
arrow PAR-19-147

Posted Date: Jan 8, 2018
Expiration Date: Jan 8, 2022
Participating Organizations: NIMH, NIA, NIDA
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.

Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21)
arrow PAR-17-335

Posted Date: July 24, 2017
Expiration Date: September 8, 2020
Participating Organizations: NIMH, NEI, NIDA, NIDCD
R21 Research Project: This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. This program creates an opportunity for integrated research in biology and chemistry on structure-activity relationships (SAR) of novel compounds through an iterative and parallel optimization process, to advance successful development of cell-based chemical probes. Applicants to this FOA should have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds.

Discovery of in vivo Chemical Probes for Novel Brain Targets (R01)
arrow PAR-17-336

Posted Date: July 24, 2017
Expiration Date: September 8, 2020
Participating Organizations: NIMH, NEI, NIDA, NIDCD
R01 Research Project: This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. This program creates an opportunity for integrated research in biology and chemistry on structure-activity relationships (SAR) of novel compounds through an iterative and parallel optimization process, to advance successful development of cell-based chemical probes. Applicants to this FOA should have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds.

Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)
arrow PAR-17-331

Posted Date: July 20, 2017
Expiration Date: September 8, 2020
Participating Organizations: NCI
R01 Research Project: The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. This FOA encourages the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01)
arrow PAR-17-189

Posted Date: March 3, 2017
Expiration Date: April 4, 2020
Participating Organizations: NICHD, NIDCD
R01 Research Project: The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. Research topics include identifying small molecules and compounds or develop biologics for new targets for pharmacological intervention.

Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK (R01)
arrow PA-16-374

Posted Date: July 21, 2016
Expiration Date: September 8, 2019
Participating Organizations: NIDDK
R01 Research Project Grant: The goal of this Funding Opportunity Announcement (FOA) is to develop, validate, or conduct a screen using a novel assay to identify therapeutic or imaging agents relevant to health related outcomes of interest to the NIDDK. It is expected that state of the art measures of basic cellular processes or molecular events that are key mediators of disease pathogenesis are incorporated into these novel assays. Such assays should be useable in screens for molecules that modulate or monitor these processes or events in an unbiased and efficient manner. In particular, the NIDDK is interested in assays utilizing phenotypic readouts that provide opportunities to measure disease-relevant endpoints and lay the groundwork for future therapeutic and imaging agent discovery and development programs. It is expected that there is significant novelty in the assay approach to be developed or library to be screened and that this is articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, or performing later-stage optimization of therapeutic or imaging agents. At the end of the project period, a successful project will have either 1) developed and validated a novel assay suitable for identifying prototype therapeutic or imaging agents or 2) utilized a novel assay to identify prototype therapeutic or imaging agents.

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01)
arrow PAR-16-266

Posted Date: May 17, 2016
Expiration Date: September 8, 2019
Participating Organizations: NIMH, NIA, NIAAA, NIDA, NIBIB
R01 Research Project - Cooperative Agreements: This Funding Opportunity Announcement (FOA) invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. Appropriate topic includes lead compound identification/development and syntheses of chemicals with suitable binding affinity, bio-distribution, pharmacokinetics, and physiochemical properties allowing radiochemical synthesis.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
arrow PAR-18-546

Posted Date: December 21, 2017
Expiration Date: May 8, 2020
Participating Organizations: NINDS, NEI, NIA, NIAAA, NICHD, NIDCR, NIDA, NIMH, NCCIH
UG3/UH3 Research Project - Cooperative Agreements: The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Projects can initiate at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development.

If you have an assay you would like to screen that cannot be funded by one of the above opportunities, please e-mail us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call us at either (561) 228-2150 or (561) 228-2101 to discuss other options available to you.

 

Leadid_Robot


Scripps Florida  |  130 Scripps Way, Jupiter, FL  33458  |  (561) 228-2000
The Scripps Research Institute  |  10550 North Torrey Pines Road, La Jolla, CA  92037  |  (858) 784-1000